For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...

If you want to take Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight management, you might also be exploring telemedicine and the convenience of getting a ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its latest trial ...

The battle between the two front runners in the vast weight loss released top-line results from the SURMOUNT-5 Phase IIIb ...

For Debbie Halstead, the weight loss medication Wegovy has been nothing short of a miracle. The Cool Ridge, West Virginia, woman shed 60 pounds and lowered her blood pressure nearly 60 points.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...